SCHEMBL6606570

SCHEMBL6606570

CC(C)(C)OC(=O)CC(NC(=O)c1ccccc1)C(=O)CCl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSG P08311 6/20 0.43
CTRB1 P17538 6/20 0.43
PRSS1 P07477 5/20 0.43
CMA1 P23946 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
PADI1 Q9ULC6 3/20 0.41
PADI3 Q9ULW8 3/20 0.41
PADI4 Q9UM07 3/20 0.41
PADI2 Q9Y2J8 2/20 0.41
CTSL P07711 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
PADI6 Q6TGC4 1/20 0.41
P2RY12 Q9H244 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6606965 0.87 CTSG (0.43) CTSGCTRB1PRSS1CMA1PADI1
SCHEMBL17731584 0.81 CASP1 (0.54) CTSLCTSK
SCHEMBL6607345 0.81 CASP3 (0.48) PADI1PADI3PADI4PADI2PDE4A
SCHEMBL8972436 0.80 RAB9A (0.52) CTSGCTRB1PRSS1CMA1SMN1; SMN2
SCHEMBL18103838 0.76 KLK5 (0.58) CTSLCTSK
SCHEMBL29946196 0.76 KLK5 (0.58) CTSLCTSK
SCHEMBL10561618 0.75 P2RY12 (0.43) CTSGCTRB1PRSS1CMA1CTSL
SCHEMBL10977546 0.74 ACE (0.49) CTSLALDH1A1CTSK
SCHEMBL15662393 0.74 EPHX2 (0.42) PTPRC
SCHEMBL6496041 0.74 ACE (0.64) CTSGCTRB1CMA1CTSLCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1163208-B1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMA (US) 2004-05-12 EP disclosed
US-6632962-B2 N-(2-carboxy-1-haloacetylethyl)arylamide derivatives as inhibitors of caspase and cellular apoptosis. VERTEX PHARMACEUTICALS INCORPORATED 2003-10-14 US disclosed
US-20020132833-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2002-09-19 US disclosed
EP-1163208-A4 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMA (US) 2002-07-03 EP disclosed
EP-1163208-A2 CASPASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2001-12-19 EP disclosed
WO-2001010383-A2 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2001-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132833-A1 Caspase inhibitors and uses thereof CASP1, CASP3, CASP7 CTSG 216/4885CTRB1 259/4885PRSS1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.